Allegiance Equity Engages Investor Relations Group
TORONTO, Sept. 22, 2011 /CNW/ - Allegiance Equity Corporation (TSX.V: ANQ) ("Allegiance") is pleased to announce that it has engaged Investor Cubed Inc. ("Investor Cubed" or "ICI") to provide investor relations and shareholder communications services.
In connection with the engagement, Investor Cubed has been awarded a consulting contract paying $5,000 per month for a term of twelve months. In addition, Investor Cubed has been granted options to purchase 120,000 shares of Allegiance at a price of sixty-two cents ($0.62) per share. The options will vest quarterly over a period of one year and will be governed by the provisions of Allegiance's stock option plan.
About Investor Cubed
Investor Cubed Inc. provides specialized investor relations and business consulting services to a select group of leading emerging and mid-capitalization public companies. Investor Cubed has an established national network of financial industry professionals including investment advisors, bank owned investment dealers and leading independent financial firms. In addition, ICI introduces and manages national online and off-line marketing initiatives.
David Solomon, President and CEO of Allegiance Equity commented, "Allegiance has reached a point in its corporate development requiring professional Investor Relations and Corporate Communications services that the team at Investor Cubed provides. He further noted that "The Company believes it is incumbent to articulate the company's strategies given the importance and significance of the products and their industry partners".
About Allegiance Equity Corporation
Allegiance targets billion dollar markets having clearly identified product deficiencies and dissatisfied patients who suffer widespread diseases and conditions including diabetes, cholesterol, Alzheimer's and Dementia and arthritis.
Allegiance's strategy utilizes leading-edge scientific technology to create valuable, proprietary and effective natural treatments, recognized as safe and effective by North American regulatory authorities, at a fraction of the cost and time it takes to develop a prescription drug. Allegiance then obtains patents and regulatory approvals.For further information:
Allegiance Equity Corporation:
David Solomon, President & CEO
Telephone: 416 630 1221
Investor Cubed Inc.:
Telephone: (647) 258-3311, (888) 258-3323
Fax: (416) 363-7977